Key result
Pharmacological adenosine receptor agonists and antagonists can elicit anti- or pro-angiogenic responses, offering a potentially novel strategy to suppress angiogenesis in tumors.
Pharmacological targeting of adenosine receptors represents a potential strategy to modulate angiogenesis in tumors.
Should not change oncology practice; leaves open adenosine receptor modulation as a hypothesis-generating anti-angiogenic research target.
OBJECTIVES: Adenosine concentration significantly increases in tumour microenvironment contributing to tumorigenic processes including cell proliferation, survival, invasion and of special interest in this review angiogenesis. KEY FINDINGS: This review summarizes the role of pharmacological adenosine receptor agonist and antagonist in regulating angiogenesis for a better understanding and hence a better management of angiogenesis-associated disorders. SUMMARY: Depending upon the pharmacological characteristics of adenosine receptor subtypes, adenosine elicits anti- or pro-angiogenic responses in stimulated cells. Inhibition of the stimulatory effect of adenosine signalling on angiogenesis using specific pharmacological adenosine receptor agonist, and antagonist is a potentially novel strategy to suppress angiogenesis in tumours.
No takes yet. Share an insight, caveat, or question.
Bahreyni et al. (2017) conducted a review in Angiogenesis-associated disorders and tumours. Pharmacological adenosine receptor agonists and antagonists was evaluated on Angiogenesis regulation. Pharmacological adenosine receptor agonists and antagonists can elicit anti- or pro-angiogenic responses, offering a potentially novel strategy to suppress angiogenesis in tumors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: